Cheng Zhou1, Yuanfei Peng1, Kaiqian Zhou1, Lan Zhang1, Xiangyu Zhang1, Lei Yu1, Jie Hu1, Feiyu Chen1, Shuangjian Qiu1, Jian Zhou1,2,3, Jia Fan1,2,3, Zhenggang Ren1, Zheng Wang1. 1. Liver Cancer Institute and Department of Liver Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. 2. Institute of Biomedical Sciences, School of Life Sciences, Fudan University, Shanghai 200032, China. 3. State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai 200032, China.
Abstract
BACKGROUND: To compare the efficacy and safety of surgical resection plus radiofrequency ablation (SR-RFA) with transarterial chemoembolization (TACE) in patients with multifocal hepatocellular carcinoma (HCC) beyond the Milan criteria. METHODS: From 2009 to 2015, a total of 469 consecutive patients with multifocal HCC beyond the Milan criteria (≤5 nodules) treated with SR-RFA (n=59) or TACE (n=410) were analyzed. Their overall survival (OS) rate was compared through propensity score matching (PSM) analysis at a ratio of 1:2, and 141 patients were identified (SR-RFA, n=47; TACE, n=94). Subgroup analysis was conducted according to factors associated with treatment options. RESULTS: Before PSM, the 1-, 2- and 3-year OS rates were 81.5%, 68.3% and 64.3% in the SR-RFA group and 58.7%, 35.5% and 24.4% in the TACE group, respectively (all P<0.001). After PSM, the 1-, 2- and 3-year OS rates in the SR-RFA group were 81.8%, 68.7% and 63.4%, whereas those in the TACE group were 59.3%, 36.1% and 19.4%, respectively (all P<0.001). Subgroup analysis also revealed a survival advantage of SR-RFA over TACE in each subgroup. The 30-day mortality rate was 1.22% in the TACE group and nil in the SR-RFA group (P=0.861). CONCLUSIONS: SR-RFA provides better a long-term survival rate than TACE for patients with multifocal HCC beyond the Milan criteria. SR-RFA may serve as an alternative treatment for patients with multifocal HCC in a selected patient population.
BACKGROUND: To compare the efficacy and safety of surgical resection plus radiofrequency ablation (SR-RFA) with transarterial chemoembolization (TACE) in patients with multifocal hepatocellular carcinoma (HCC) beyond the Milan criteria. METHODS: From 2009 to 2015, a total of 469 consecutive patients with multifocal HCC beyond the Milan criteria (≤5 nodules) treated with SR-RFA (n=59) or TACE (n=410) were analyzed. Their overall survival (OS) rate was compared through propensity score matching (PSM) analysis at a ratio of 1:2, and 141 patients were identified (SR-RFA, n=47; TACE, n=94). Subgroup analysis was conducted according to factors associated with treatment options. RESULTS: Before PSM, the 1-, 2- and 3-year OS rates were 81.5%, 68.3% and 64.3% in the SR-RFA group and 58.7%, 35.5% and 24.4% in the TACE group, respectively (all P<0.001). After PSM, the 1-, 2- and 3-year OS rates in the SR-RFA group were 81.8%, 68.7% and 63.4%, whereas those in the TACE group were 59.3%, 36.1% and 19.4%, respectively (all P<0.001). Subgroup analysis also revealed a survival advantage of SR-RFA over TACE in each subgroup. The 30-day mortality rate was 1.22% in the TACE group and nil in the SR-RFA group (P=0.861). CONCLUSIONS: SR-RFA provides better a long-term survival rate than TACE for patients with multifocal HCC beyond the Milan criteria. SR-RFA may serve as an alternative treatment for patients with multifocal HCC in a selected patient population.
Authors: J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés Journal: J Hepatol Date: 2001-09 Impact factor: 25.083
Authors: X D Zhou; Z Y Tang; B H Yang; Z Y Lin; Z C Ma; S L Ye; Z Q Wu; J Fan; L X Qin; B H Zheng Journal: Cancer Date: 2001-04-15 Impact factor: 6.860
Authors: Tan To Cheung; Kelvin K Ng; Kenneth S Chok; See Ching Chan; Ronnie T Poon; Chung Mau Lo; Sheung Tat Fan Journal: World J Gastroenterol Date: 2010-06-28 Impact factor: 5.742
Authors: R M Eisele; J Zhukowa; S Chopra; S C Schmidt; U Neumann; J Pratschke; G Schumacher Journal: Eur J Surg Oncol Date: 2009-09-01 Impact factor: 4.424
Authors: Yousra M El-Far; Ahmed E Khodir; Ziad A Emarah; Mohamed A Ebrahim; Mohammed M H Al-Gayyar Journal: Redox Rep Date: 2022-12 Impact factor: 4.412